STOCK TITAN
  1. Home
  2. News
  3. SXTP

60 Degrees Pharmaceuticals, Inc. - $SXTP STOCK NEWS

Welcome to our dedicated page for 60 Degrees Pharmaceuticals news (Ticker: $SXTP), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 60 Degrees Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 60 Degrees Pharmaceuticals's position in the market.

News
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. announced the pricing of its public offering of 5,260,901 units and 999,076 pre-funded units at $0.385 and $0.375 per unit respectively. Each unit consists of one share of common stock and one warrant exercisable for one share of common stock. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.62%
Tags
offering
-
News
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) plans to conduct a pivotal clinical study for the treatment of hospitalized babesiosis patients with tafenoquine following a Type C meeting with FDA. The FDA indicated that the proposed study could be sufficient for regulatory approval, provided the Company uses a clinical endpoint rather than a surrogate marker. Patient enrollment is expected to begin in the summer of 2024. The company aims to address the unmet medical need for a new therapeutic for hospitalized babesiosis patients, with an estimated 47,000 cases per year in the U.S. Tafenoquine is currently approved for malaria prophylaxis and has been assessed in multiple trials for safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.97%
Tags
none
-
News
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) has announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market after receiving a written notice from the Nasdaq Listing Qualifications Staff. The Company was previously notified of non-compliance due to its common stock failing to maintain a minimum bid price of $1.00 for 30 consecutive business days. However, it has now achieved compliance by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
News
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced the Investigational Review Board (IRB) approval for a Phase IIA clinical study to investigate tafenoquine for the treatment of hospitalized babesiosis patients. The previously announced Type C meeting with the FDA has been rescheduled to January 17, 2024, due to a federal holiday.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.05%
Tags
acquisition clinical trial
-
News
Thinking about buying stock in Sportsmap Tech Acquisition, Dune Acquisition, Macy's, Cybin, or 60 Degrees Pharmaceuticals?
Rhea-AI Summary
InvestorsObserver Critical PriceWatch Alerts: MSAI, DUNE, M, CYBN, and SXTP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
acquisition
-
News
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease
Rhea-AI Summary
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced a Type C meeting with the FDA to discuss a proposed Phase II study of tafenoquine for the treatment of babesiosis, a life-threatening parasitic disease transmitted by ticks. The meeting is scheduled for January 15, 2024. Tafenoquine is currently approved for malaria prophylaxis but not for babesiosis treatment. The Company plans to conduct a clinical study to evaluate its use for this purpose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.97%
Tags
acquisition
News
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston
Rhea-AI Summary
60 Degrees Pharmaceuticals will present scientific poster on new, long-term safety data on the use of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.18%
Tags
conferences
-
News
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases
Rhea-AI Summary
60 Degrees Pharmaceuticals focuses on commercialization of ARAKODA® and plans Phase IIA study of tafenoquine for babesiosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.69%
Tags
clinical trial covid-19
-
News
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
Rhea-AI Summary
60P Australia withdraws IND for ACLR8-LR study of tafenoquine in treating COVID-19; plans to resubmit later in 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.45%
Tags
clinical trial covid-19
News
60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
60 Degrees Pharmaceuticals Inc. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
Stock SXTP logo
60 Degrees Pharmaceuticals, Inc.

Nasdaq:SXTP

SXTP Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SXTP Stock Data

2.60M
8.57M
25.42%
3.35%
0.61%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
WASHINGTON